Abstract. MicroRNAs (miRs) have been demonstrated to be important regulators of malignant behavior in nasopharyngeal carcinoma (NPC) tumorigenesis. The present study aimed to investigate the biological roles and underlying mechanisms of miR-379 in NPC. The study initially observed that miR-379 was significantly downregulated in NPC clinical tissues and cell lines using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Next, gain-of-function assays were performed on human the NPC cell lines, C666-1 and 5-8F, including MTT, colony formation and transwell migration assays. The results indicated that ectopic expression of miR-379 suppressed the NPC cell proliferation, colony formation, migration and invasion in vitro. In addition, tumor protein D52 (TPD52) was identified as a direct target of miR-379 by a dual-luciferase reporter assay, while overexpression of miR-379 markedly reduced TPD52 expression at the mRNA and protein levels, as determined by RT-qPCR and western blot analysis, respectively. Furthermore, silencing of TPD52 significantly inhibited the C666-1 cell proliferation, migration and invasion. These findings suggest that miR-379 negatively regulates the growth and migration of NPC cells by downregulating TPD52 expression, while modulation of miR-379 expression may be a therapeutic strategy for NPC.

Introduction

Nasopharyngeal carcinoma (NPC) is an aggressive epithelial tumor associated with Epstein-Barr virus (1). It is particularly prevalent in Southern China with an incidence of 25-30 cases per 100,000 individuals annually; however, NPC is rare in Western Europe and North America (2). Although conventional treatment strategies with radiotherapy and chemotherapy improve the survival rate for localized NPC, patients with advanced metastatic tumors have a poor clinical outcome (3). Therefore, understanding the molecular mechanisms underlying NPC tumorigenesis and progression would contribute to the development of novel therapeutic strategies.

MicroRNAs (miRs) are small endogenous non-coding RNAs (20-24 nucleotides in length) that function as post-transcriptional regulators by suppressing translation or cleaving mRNA targets in a complete or incomplete complementary manner (4). A large body of evidence has suggested that miRs are often dysregulated in human malignancies, and exert oncogenic or tumor suppressor properties by regulating several cellular processes, including initiation, proliferation, invasion and apoptosis (5). In human NPC, certain miRs have been reported to be abnormally upregulated or downregulated and involved in tumor progression, including miR-200a (6), miR-144 (7), miR-let-7 (8) and miR-216b (9). For instance, miR-200a is frequently downregulated in NPC, while overexpression of miR-200a has an inhibitory role on oncogenesis (6). miR-144 is aberrantly upregulated in NPC tissues and cell lines, and inhibition of miR-144 impedes proliferation, colony formation, invasiveness and tumorigenesis in nude mice (7). Furthermore, miR-let-7 is downregulated in NPC cells, and overexpression of let-7 by transfection of let-7 precursor molecules resulted in the suppression of cell proliferation (8).

MicroRNA-379 is located on the human chromosome region 14q32 and forms a large cluster with other miRs (10). Accumulating evidence indicated that miR-379 serves a tumor-suppressive role in several tumors, including bladder cancer (11), osteosarcoma (12) and melanoma (10). In addition, restoration of miR-379 significantly weakens the cell proliferation by modulating Cyclin B1 in breast cancer cells (13). However, the expression profile of miR-379 in NPC, as well as its role in this tumor has not yet been identified.

miR-379 is located on the human chromosome region 14q32 and forms a large cluster with other miRs (10). Accumulating evidence indicated that miR-379 serves a tumor-suppressive role in several tumors, including bladder cancer (11), osteosarcoma (12) and melanoma (10). In addition, restoration of miR-379 significantly weakens the cell proliferation by modulating Cyclin B1 in breast cancer cells (13). However, the expression profile of miR-379 in NPC, as well as its role in this tumor has not yet been identified.

Tumor protein D52 (TPD52), contains a small coiled-coil motif and mapping to chromosome 8q21 (14). It was first identified in human breast carcinoma though amplification (15). Accumulating evidence revealed that TPD52 served oncogenic roles in tumor growth, metastasis and maintenance (16). Loss of TPD52 function has been demonstrated to be associated with decreased proliferation and colony formation in glioma (17) and liver cancer cells (18). Furthermore, TPD52
was observed to be regulated by specific miRs implicated in cancer progression, including miR-224 (19), miR-218 (20) and miR-34a (21). In particular, miR-224 attenuated prostate cancer cell migration and invasion via targeting TPD52 (22). In addition, miR-218 mediated the suppression of proliferation and induction of apoptosis though repression of TPD52 in prostate cancer (23). These findings suggest that TPD52 serves oncogenic roles in tumor growth, metastasis and maintenance, is regulated by specific miRs and is involved in various types of cancer. Thus, it is hypothesized that there may be a close association between miR-379 and TPD52 in NPC.

Therefore, the present study initially characterized the miR-379 expression profile and its biological function in NPC specimens and cells. The effects of miR-379 overexpression on cell proliferation, migration and invasion phenotypes were further investigated in the two NPC cell lines. Furthermore, it was investigated whether TPD52 was a direct target of miR-379 in NPC. Investigation of the functional relevance of miR-379 in NPC and targeting of TPD52 will provide a deeper understanding of the tumorigenesis and metastasis of NPC.

Materials and methods

Tissue collection. A total 30 pairs of NPC specimens (age range, 38-56; mean age, 44.3, including 18 males and 12 females) and the corresponding adjacent non-tumor nasopharyngeal epithelial tissues were collected from patients, who had not received any radiotherapy or chemotherapy treatment prior to biopsy at Jiangsu Taizhou People's Hospital (Taizhou, China) between March 2014 and May 2016. All samples were reviewed by pathologists to confirm the diagnosis. The clinicopathological information of these patients is listed in Table I. The clinical stage was defined based on the International Union Against Cancer (24). All patients provided written informed consent for the use of clinical materials, and the current study was approved by the Institutional Ethics Committee at Jiangsu Taizhou People's Hospital.

Cell culture. The human NPC cell lines, C666-1 (cat. no. ZY-H275), 5-8F (cat. no. FS-0140) and SUNE1 (cat. no. AM-456; all American Type Culture Collection, Manassas, VA, USA), were cultured in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc.), Waltham, MA, USA) with 10% fetal bovine serum (FBS). The immortalized nonmalignant human nasopharyngeal epithelial cell line NP69 was kindly provided by Professor Kaitai Yao from Southern Medical University (Guangzhou, China) and cultured in keratinocyte-serum free medium (Invitrogen; Thermo Fisher Scientific, Inc.) containing bovine pituitary extract (BD Biosciences, San Jose, CA, USA). All cell lines were maintained in a humidified incubator containing 5% CO₂ at 37°C.

Oligonucleotides and cell transfection. The miR-379 mimics (5'-UGGUAGACAUUGGAACGUAGG-3'; cat. no. 31263570), small interfering RNA for TPD52 (siTPD52: 5’-UUCUCCGAACGUGUCAGCTT-3'; cat. no. 31635420) and their corresponding negative controls (NC mimics (5'-GUGGAUUUCCUCAUGAAUUU-3') and NC siRNA (5'-UUCUCCGAACGUGUCAGTTT-3')) were chemically synthesized by GenePharma Co., Ltd. (Shanghai, China). For cell transfection, C666-1 and 5-8F cells in the logarithmic growth phase were cultured in a 24-well plate at a density of 2x10⁴ cells/well, and directly prepared transfection complexes were added using the Lipofectamine 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. After 48 h of transfection at 37°C, the cells were collected for subsequent experiments.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) from the tumor tissues or cells, according to the manufacturer's protocol. An ultraviolet spectrophotometer was used to determine the purity and concentration of the extracted RNA. Complementary DNA was synthesized using M-MLV reverse transcriptase (Promega Corp., Madison, WI, USA). The expression levels of miR-379 were determined using Platinum SYBR Green qPCR SuperMix-UDG reagents (Invitrogen; Thermo Fisher Scientific, Inc.). In addition, the expression levels of TPD52 were measured using the Platinum SYBR Green qPCR SuperMix-UDG reagent (Invitrogen; Thermo Fisher Scientific, Inc.). All qPCR reactions were performed on the 7500 Fast System Real-Time PCR cycler (Applied Biosystems; Thermo Fisher Scientific, Inc.) at 94°C for 2 min, followed by 40 cycles of 94°C for 20 sec, 58°C for 20 sec and 72°C for 20 sec. The primers used for PCR amplifications were as follows: miR-379 forward, 5'-GCT CATGATAACGTGCAAA-3', and reverse, 5’-AGTTGTTCCTGACCCCTTCAG-3'; TPD52 forward, 5'-AAGAGACACAGGCAGAAGGGA-3', and reverse, 5'-GCTGGGTCCGAGGCAGGACCAAA-3'. U6 forward, 5'-CTGCCTTCCGGCA GCACA-3', and reverse, 5'-AAGCGCTTCACAAGATTTTC GT-3'; GAPDH forward, 5'-TTGTTCGTATGGGTGTGAC AC-3', and reverse, 5'-ATGCATGGACTGTGGTCAT-3'. U6 or GAPDH was used as normalization controls for the determination of the miR-379 or TPD52 mRNA expression, respectively. Three replicates of each sample were prepared and run three times. The results were analyzed using the 2-ΔΔCq method (25).

Western blot analysis. Treated cells were washed with phosphate-buffered saline (PBS) and lysed in lysis radioimmunoprecipitation assay buffer (Cell Signaling Technology, Inc., Danvers, MA, USA). Lysates were then centrifuged for 10 min at 7,043.4 x g at 4°C, the supernatants were collected, and the protein concentration was quantified using the Bradford assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Aliquots of 20 μg protein were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Subsequent to washing with Tris-buffered saline (TBS), the membranes were blocked with TBS containing 5% skim milk and incubated with specific anti-TPD52 (1:1,000; cat. no. 2847; Cell Signaling Technology, Inc.) and anti-GAPDH antibodies (1:5,000; cat. no. 10494-1-AP; ProteinTech Group, Inc., Chicago, IL, USA) overnight at 4°C. Next, the membranes were incubated with the horseradish peroxidase (HRP)-conjugated secondary antibody (1:5,000; cat. no. 2534; Cell Signaling Technology, Inc.) at room temperature for 2 h. The signal intensity was detected with an enhanced chemiluminescence substrate kit.
Table I. Clinicopathological characteristics of nasopharyngeal carcinoma patient samples (n=30).

| Characteristics                  | No. of cases |
|----------------------------------|-------------|
| Age (years)                      |             |
| <50                              | 24          |
| ≥50                              | 6           |
| Sex                              |             |
| Male                             | 18          |
| Female                           | 12          |
| Clinical stage                   |             |
| I and II                         | 25          |
| III and IV                       | 5           |
| Lymph node metastasis            |             |
| Yes                              | 16          |
| No                               | 14          |

*According to the International Union Against Cancer.

Prediction of miR-379 target genes. The potential downstream targets of miR-379 were predicted using TargetScan (http://www.target-scan.org/index.html), miRanda (http://www.microrna.org/microrna/home.do) and PicTar (http://pictar.mdc-berlin.de). Genes that were predicted by all three databases were considered as potential targets. TPD52, one of the identified targets, was selected for further analysis.

Dual-luciferase reporter assay. The pGL3-TPD52 3’-untranslated region (3’UTR) wild-type (WT) and pGL3-TPD52 3’UTR mutant (MUT) luciferase plasmids (GenePharma Co., Ltd.) were used in dual-luciferase reporter assay. Briefly, cells were seeded in 12-well plates at a density of 2x10^4 cells/well and transfected with miR-379 mimics or NC, and co-transfected with WT or MUT using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). At 48 h after transfection, the luciferase activity was measured using a Dual-Luciferase Reporter Assay kit (Promega Corp.) according to the manufacturer's protocol. The firefly luciferase activity was normalized to the Renilla luciferase activity. Three replicates of each sample were prepared and run three times.

Statistical analysis. Data are presented as the mean ± standard deviation, and analyzed using SPSS software (version 17; SPSS, Inc., Chicago, IL, USA). Two treatment groups were compared by the unpaired Student's t-test, and P<0.05 was considered to indicate a statistically significant difference.

Results

miR-379 expression is significantly downregulated in NPC tissues and cell lines. To investigate the functional role of miR-379 in NPC, the expression of this miR was initially analyzed in 30 pairs of NPC samples and the corresponding adjacent non-tumor nasopharyngeal epithelial tissues using RT-qPCR. As shown in Fig. 1A, the expression of miR-379 was significantly decreased in NPC tissues compared with the normal nasopharyngeal epithelial tissues (P<0.001). Subsequently, miR-379 expression in three NPC cell lines (C666-1, 5-8F and SUNE1) was examined and observed to be significantly downregulated when compared with the normal nasopharyngeal epithelial cell line NP69 (P<0.01; Fig. 1B). These findings provided novel evidence of the downregulation of miR-379 in human NPC clinical specimens and cell lines.

Elevated miR-379 inhibits the NPC cell proliferation and colony formation in vitro. Since reduced expression of miR-379 was observed in NPC cells, the study then investigated whether restoration of miR-379 expression was capable of inhibiting NPC cell growth. The C666-1 and 5-8F NPC cell lines presented the lowest expression of miR-379, and thus were selected for the gain-of-function assays. C666-1 and 5-8F NPC cells were first transfected with miR-379 mimics or NC, and the induced miR-379 expression upregulation was confirmed by RT-qPCR in these two cell lines (Fig. 2A; P<0.001). Using an MTT assay as a measure of cell proliferation, it was observed that the elevated miR-379 expression suppressed the mimic-transfected C666-1 and 5-8F cell proliferation when compared with that of the scramble-infected cells.
ZHAO and CHU: miR-379 SUPPRESSES NPC BY TARGETING TPD52

(2B; $P<0.05$). Consistently, the colony formation assay also indicated that upregulation of miR-379 inhibited the colony formation ability in the C666-1 and 5-8F cells ($P<0.01$ and $P<0.001$, respectively; Fig. 2C).

**Elevated miR-379 suppresses NPC cell migration and invasion in vitro.** The effect of miR-379 on the NPC cell migration and invasion ability was next examined using transwell migration and Matrigel invasion assays, respectively. As shown in Fig. 3A, when transfected with miR-379 mimics, the cell migration ability of C666-1 and 5-8F cells was significantly reduced ($P<0.05$ and $P<0.01$, respectively). The capacity for invasion was also evidently reduced in the two cell lines transfected with miR-379 mimics ($P<0.01$ and $P<0.05$, respectively).
respectively; Fig. 3B). These results suggest that miR-379 was able to markedly suppress the in vitro migration and invasion of NPC cells.

miR-379 directly targets TPD52 in NPC cells. To explore the mechanism underlying the effect of miR-379 on the cell proliferation, migration and invasion, bioinformatics tools were used to search for potential targets of miR-379. Among various targets, TPD52 was focused on since it is involved in cancer oncogenesis and metastasis. TargetScan prediction revealed that the 3’UTR of TPD52 contains a conserved binding site for miR-379 (Fig. 4A). Subsequently, the dual-luciferase reporter assay demonstrated that TPD52 is a target gene of miR-379 in C666-1 and 5-8F cells, which was confirmed by the markedly reduced luciferase assay in the mimic and WT co-transfected cells (P<0.05; Fig. 4B). Furthermore, RT-qPCR (P<0.05; Fig. 4C) and western blot analysis (Fig. 4D) demonstrated that overexpression of miR-379 inhibited the transcription of TPD52 gene and the expression of TPD52 protein. Overall, these results confirmed that TPD52 is a target gene of miR-379 in NPC cells.

Knockdown of TPD52 inhibits NPC cell proliferation, migration and invasion. To investigate the functional role of TPD52 in NPC, loss-of-function studies were performed using siTPD52 transfection. Initially, the knockdown efficiency of siTPD52 transfection was evaluated in C666-1 cells. Western blot analysis indicated that siTPD52 transfection effectively downregulated TPD52 expression in C666-1 cells (Fig. 5A). In functional assays with MTT, it was demonstrated that cell proliferation was inhibited by transfection with siTPD52 in comparison with the NC-transfected cells (P<0.001; Fig. 5B). In addition, knockdown of TPD52 significantly suppressed the NPC cell migration and invasion (P<0.001; Fig. 5C).

Discussion

miR dysregulation is a common and frequent event in cancer, which drives tumorigenesis and tumor development (26). The specific and complex pathogenesis of NPC has yet to be fully clarified (27), and there are currently no effective treatment strategies for this tumor, particularly in patients with metastatic NPC. Therefore, investigation of differentially expressed miRs in NPC will provide an insight into the complex molecular mechanisms underlying the progression and metastasis of this disease.

To the best of our knowledge, the present study displayed for the first time that the expression of miR-379 is reduced
in NPC samples and cell lines. Next, the C666-1 and 5-8F cell lines were subjected to gain-of-function studies in order to examine the biological behavior of miR-379 in NPC. The results revealed that overexpression of miR-379 significantly blocked the cancer cell proliferation, colony formation, migration and invasion. These results indicated that miR-379 exerts an anti-tumor effect on NPC growth. To date, a relatively low basal miR-379 has been observed in a variety of cancer types, including breast cancer (13) and osteosarcoma (28). It has been demonstrated that miR-379 functions to attenuate the progression of osteosarcoma and breast cancer by targeting pyruvate dehydrogenase kinase 1 (PDK1) and Cyclin B1, respectively. However, the upregulation of miR-379 was detected in specimens of prostate cancer, which contributes to tumor bone metastasis and epithelial-mesenchymal transition (29). Collectively, these results indicate that the distinctive expression and function of miR-379 is dependent on the cancer type.

miRs function to regulate gene expression at the post-transcriptional levels by controlling mRNA translation or degradation (30). More than 30% of human genes are considered to be regulated by miRs (31). Furthermore, downregulation of tumor suppressor genes, including miRs, may be linked with the upregulation of oncogenes in cancer development. TPD52 is considered as an oncogene that is overexpressed in various types of cancer, including breast cancer (32), prostate cancer (20) and ovarian carcinoma (33). In addition, TPD52 has been demonstrated to be regulated by specific miRs, including miR-200a (6), miR-144 (7), miR-let-7 (8) and miR-216b (9). Thus, in the present study, it was hypothesized that TPD52 may be a target gene of miR-379 in NPC cells.
The results of the current study identified that miR-379 binds directly to the TPD52 3'UTR, which suggests that TPD52 is a direct target of miR-379 in NPC. In addition, overexpression of miR-379 reduced TPD52 mRNA and protein expression levels, suggesting that miR-379 negatively regulated the TPD52 protein synthesis though degradation of the mRNA. Recently, a previous study revealed that elevated TPD52 levels may promote the migration and proliferation of prostate cancer LNCaP cells though activation of nuclear factor-κB signaling (34). Consistently, the present study observed that the knockdown of TPD52 was able to inhibit the growth, migration and invasion of NPC cells. Thus, it was confirmed that the tumor suppressor miR-379 partially inhibited the oncogene TPD52 and, therefore, contributes to the inhibition of NPC cell growth and metastasis. However, further research is required to explore the exact molecular mechanisms of miR-379 and TPD52 in NPC. In addition, there are certain limitations in the present study, including the lack of miR-379 downregulation or TPD52 overexpression, and in vivo animal experiments, which will be investigated in further studies.

In conclusion, the current preliminary study revealed that TPD52 is a direct downstream target of miR-379. Furthermore, miR-379 resulted in the inhibition of cell proliferation, colony formation, invasion and migration, possibly by targeting TPD52 in the NPC cells. It will be valuable to understand the molecular mechanisms participating in NPC development and growth, and to provide further insight for developing novel strategies against NPC.

Acknowledgements

Not applicable.
Funding
No funding was received.

Availability of data and materials
All data generated or analyzed during the current study are included in this published article.

Authors' contributions
JC is major contributor and participated in the design of study. XZ and JC performed the experiments, participated in the interpretation of data and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The authors declare that they have no competing interests.

Competing interests
The authors declare that they have no competing interests.

References
1. Raab-Traub N: Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12: 431-441, 2002.
2. Breda E, Catarino R, Azevedo L, Lobão M, Monteiro E and Medeiros R: Epstein-Barr virus detection in nasopharyngeal carcinoma: Implications in a low-risk area. Braz J Otorhinolaryngol 76: 301-315, 2010.
3. Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, Chee CL, Ng J, Kao K, Lim WT, et al: Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22: 132-139, 2014.
4. Kavitha N, Vijayarathna S, Jothy SL, Oon CE, Chen Y, Kanwar JR and Susidharan S: microRNAs: Biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and progression. Asian Pac J Cancer Prev 15: 7489-7497, 2014.
5. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
6. Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian XW, Kung HF and Lin MC: miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun 391: 535-541, 2010.
7. Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY and Fu L: MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 34: 454-463, 2013.
8. Wong TS, Man OY, Tsang CM, Tsao SW, Tsang RK, Chan JY, Ho WK, Wei WI and To VS: MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J Cancer Res Clin Oncol 137: 415-422, 2011.
9. Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, Ye Q, Zeng X, Liao Q, Guo X, et al: miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci 124: 2997-3005, 2011.
10. Zehavi L, Avraham R, Barziali A, Bar-Ilan D, Navon R, Sidi Y, Avni D and Leibowitz-Amir R: Silencing of a large microRNA cluster on human chromosome 14q22 in melanoma: Biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Mol Cancer 11: 44, 2012.
11. Wang L, Wu H, Wang L, Zhang H, Lu J, Liang Z and Liu T: Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms. Cancer Lett 398: 24-36, 2017.
12. Xie X, Li YS, Xiao WF, Deng ZH, He HB, Liu Q and Luo W: MicroRNA-379 inhibits the proliferation, migration and invasion of human osteosarcoma cells by targeting EIF4G2. Biosci Rep 37: BSR20160542, 2017.
13. Khan S, Brougham CL, Ryan J, Sahrudin A, O'Neill G, Wall D, Curran C, Newell J, Kerin MJ and Dwyer RM: miR-379 regulates cyclin B1 expression and is decreased in breast cancer. PLoS One 8: e68753, 2013.
14. Wilson SH, Bailey AM, Nourse CR, Mattei MG and Byrne JA: Identification of MAL2, a novel member of the mal proteolipid family, though interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics 76: 81-88, 2001.
15. Cao Q, Chen J, Zhu L, Liu Y, Zhou Z, Sha J, Wang S and Li J: A testis-specific and testis developmentally regulated tumor protein D52 (TDSP2) like protein TPD52L3 interacts with TPD52 in family proteins. Biochem Biophys Res Commun 344: 798-806, 2006.
16. Byrne JA, Frost S, Chen Y and Bright RK: Tumor protein D52 (TDSP2) and cancer oncogene understudy or understudied oncogene? Tumour Biol 35: 7369-7382, 2014.
17. Wang Z, Sun J, Zhao Y, Guo W, Lv K and Zhang Q: Lentivirus-mediated knockdown of tumor protein D52-like 2 inhibits gliomacell proliferation. Cell Mol Biol (Noisy-le-grand) 60: 39-44, 2014.
18. Pan ZY, Yang Y, Pan H, Zhang J, Liu H, Yang Y, Huang G, Yin L, Jiang J and Zhao WP: Lentivirus-mediated TPD52L3 depletion inhibits the proliferation of liver cancer cells in vitro. Int J Clin Exp Med 8: 2334-2341, 2015.
19. Inoguchi S, Seki N, Chiyomaru T, Ishihara T, Matsushita M, Mafakti I, Itsako T, Tatarano S, Yoshino H, Goto Y, et al: Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer. FEBS Lett 588: 3170-3179, 2014.
20. Han G, Fan M and Zhang X: microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TDP52 expression. Biochem Biophys Res Commun 456: 804-809, 2015.
21. Li G, Yao L, Zhang J, Li X, Dang S, Zeng K, Zhou Y and Gao F: Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TDP52. Tumour Biol 37: 7481-7491, 2016.
22. Goto Y, Nishikawa K, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa M, et al: Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TDP52 in prostate cancer. FEBS Lett 588: 1973-1982, 2014.
23. Jin H, Yu Y, Hu Y, Li C, Li J, Gu J, Zhang L, Huang H, Zhang D, Wu XR, et al: Divergent behaviors and underlying mechanisms of cell migration and invasion in non-metastatic T24 and its metastatic derivative T24T bladder cancer cell lines. Oncotarget 6: 522-536, 2015.
24. Ren Y, Qiu H, Yuan Y, Ye J, Tian Y, Wen B, Zhang W and Li Q: Evaluation of 7th edition of AJCC staging system for nasopharyngeal carcinoma. J Cancer 8: 1665-1672, 2017.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
26. Baer C, Claus R and Plass C: Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res 73: 473-477, 2013.
27. Chang ET and Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1665-1672, 2006.
28. Li Z, Shen J, Chan MT and Wu WK: MicroRNA-379 suppresses osteosarcoma progression by targeting PDK1. J Cell Mol Med 21: 315-323, 2017.
30. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
31. Bhattacharyya SN, Habermacher R, Martine U, Closs EI and Filipowicz W: Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 125: 1111-1124, 2006.
32. Shehata M, Bieche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R and Byrne JA: Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Cancer Res 14: 5050-5060, 2008.
33. Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, et al: MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer 10: 497, 2010.
34. Dasari C, Yaghnam DP, Walther R and Ummanni R: Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-xB transactivation in LNCaP cells. Tumour Biol 39: 1010428317698382, 2017.